161 results on '"Koga, Takamasa"'
Search Results
2. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
3. Assessment of effectiveness and safety of thrombolytic therapy to pulmonary emboli by endobronchial ultrasound-guided transbronchial needle injection
4. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
5. Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy
6. Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study
7. Imaging Microbubbles With Contrast-Enhanced Endobronchial Ultrasound
8. Preclinical feasibility of bronchoscopic fluorescence-guided lung sentinel lymph node mapping
9. Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas
10. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
11. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
12. Imaging Microbubbles With Contrast-Enhanced Endobronchial Ultrasound
13. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
14. The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery
15. Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non–Small Cell Lung Cancers: Analysis of Five Cases
16. Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer
17. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
18. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion
19. Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis
20. Abstract 4755: Screening non-small cell lung cancer organoids with epigenetic probes
21. An Update on Clinicopathological, Imaging, and Genetic Features of Angioleiomyoma
22. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis
23. Novel approach to pleurodesis with 50 % glucose for air leakage after lung resection or pneumothorax
24. Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-
25. Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
26. Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC
27. Additional file 1 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
28. Spatiotemporal expression of Prdm genes during Xenopus development
29. Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
30. Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
31. MO14-3 Establishment of patient derived organoids from resected primary lung cancer as an in vitro model for drug screening
32. Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
33. Activity oftarloxotinib‐Ein cells withEGFRexon‐20 insertion mutations and mechanisms of acquired resistance
34. Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer
35. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study
36. Establishment of a new human malignant fibrous histiocytoma cell line, FU-MFH-1: cytogenetic characterization by comparative genomic hybridization and fluorescence in situ hybridization
37. Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance.
38. Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors
39. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
40. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
41. Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis
42. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
43. P1.05-039 Recurrence and Survival Outcome after Segmentectomy for Non-Small Cell Lung Cancer: A Long-Term Follow-Up Study at a Single Institute
44. Two cases of organ infarction due to thrombus in pulmonary vein stump after left lung lobectomy
45. Novel approach to pleurodesis with 50 % glucose for air leakage after lung resection or pneumothorax
46. Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
47. Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer
48. EGFRT790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
49. Secondary Mutations of the EGFRGene That Confer Resistance to Mobocertinib in EGFRExon 20 Insertion
50. Effects of differences in level of knee pain and affected side on mental health in elderly
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.